167 related articles for article (PubMed ID: 3042577)
1. High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells.
Suzuki Y; Ichihara T; Nakao A; Sakamoto J; Takagi H; Nagura H
Hepatogastroenterology; 1988 Jun; 35(3):128-35. PubMed ID: 3042577
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
[TBL] [Abstract][Full Text] [Related]
4. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels.
Hirano K; Kawa S; Oguchi H; Kobayashi T; Yonekura H; Ogata H; Homma T
J Natl Cancer Inst; 1987 Dec; 79(6):1261-8. PubMed ID: 2447318
[TBL] [Abstract][Full Text] [Related]
5. [Pancreatic oncofetal antigen (POA) and carcinoma of the pancreas].
Homma T; Oguchi H; Kawa S; Nagata A; Furuta S
Gan No Rinsho; 1984 May; 30(6 Suppl):558-62. PubMed ID: 6205174
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
7. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of CA 19-9, DU-PAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma.
Tempero M; Takasaki H; Uchida E; Takiyama Y; Colcher D; Metzgar RS; Pour PM
Am J Surg Pathol; 1989; 13 Suppl 1():89-95. PubMed ID: 2699170
[TBL] [Abstract][Full Text] [Related]
9. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
10. [Clinical investigation of carbohydrate antigen CA-50].
Ishii M; Abe O; Okura H; Okazaki N; Kawai T; Saito Y; Sawabu N; Takamizawa Y; Takeuchi T; Niitani H
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2548-55. PubMed ID: 3304170
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of tumor-associated antigen of the digestive tract by monoclonal antibody].
Imai K; Hinoda Y; Yachi A
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2185-90. PubMed ID: 3606145
[TBL] [Abstract][Full Text] [Related]
12. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
[TBL] [Abstract][Full Text] [Related]
13. Distribution of lung adenocarcinoma-associated antigens in human tissues and sera defined by monoclonal antibodies KM-52 and KM-93.
Shitara K; Hanai N; Yoshida H
Cancer Res; 1987 Mar; 47(5):1267-72. PubMed ID: 3545444
[TBL] [Abstract][Full Text] [Related]
14. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
[TBL] [Abstract][Full Text] [Related]
15. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
16. [Pancreatic cancer-associated new carbohydrate antigen].
Yuan M
Zhonghua Zhong Liu Za Zhi; 1987 May; 9(3):183-6, 11. PubMed ID: 2452061
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
18. [Early detection of pancreatic cancer by serum markers].
Nakae Y; Naruse S; Shibata T; Kitagawa M; Kondo T; Hayakawa T; Kuno N; Kurimoto K
Rinsho Byori; 1994 Feb; 42(2):139-42. PubMed ID: 7511183
[TBL] [Abstract][Full Text] [Related]
19. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.
Tempero MA; Uchida E; Takasaki H; Burnett DA; Steplewski Z; Pour PM
Cancer Res; 1987 Oct; 47(20):5501-3. PubMed ID: 3308077
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer].
Nishida K
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]